Cargando…

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program

PURPOSE: Data on the safety of growth hormone (GH) replacement therapy during pregnancy are limited. We report a combined analysis of data from pregnant women treated with GH while enrolled in two non-interventional, multicenter studies: NordiNet® International Outcome Study (IOS) and the American N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biller, Beverly M. K., Höybye, Charlotte, Carroll, Paul, Gordon, Murray B., Birkegård, Anna Camilla, Kelepouris, Nicky, Nedjatian, Navid, Weber, Matthias M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270875/ https://www.ncbi.nlm.nih.gov/pubmed/33709288 http://dx.doi.org/10.1007/s11102-021-01138-3

Ejemplares similares

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
por: Biller, Beverly M K, et al.
Publicado: (2023)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program
por: Backeljauw, Philippe, et al.
Publicado: (2023)

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER
por: Sävendahl, Lars, et al.
Publicado: (2021)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
por: Höybye, Charlotte, et al.
Publicado: (2013)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS
por: Ross, Judith L, et al.
Publicado: (2022)

CORRIGENDUM for “Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program”
Publicado: (2020)

Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program
por: Lee, Peter A., et al.
Publicado: (2015)

Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet® International Outcome Study
por: Blankenstein, Oliver, et al.
Publicado: (2017)

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use
por: Hokken-Koelega, Anita, et al.
Publicado: (2011)

Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study
por: Polak, Michel, et al.
Publicado: (2017)

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
por: Höybye, Charlotte, et al.
Publicado: (2022)

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013)

User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum]
Publicado: (2013)

SAT-282 Outcomes in Children Treated with Growth Hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS)
por: Angulo, Moris, et al.
Publicado: (2019)

Developments in administration of growth hormone treatment: focus on Norditropin(®) Flexpro(®)
por: Yuen, Kevin CJ, et al.
Publicado: (2011)

Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry
por: Lee, Peter A, et al.
Publicado: (2012)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort
por: Grundmann, Eva, et al.
Publicado: (2023)

Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)
por: Vyberg, Mogens, et al.
Publicado: (2015)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Development of a Novel Algorithm to Identify People with High Likelihood of Adult Growth Hormone Deficiency in a US Healthcare Claims Database
por: Yuen, Kevin C. J., et al.
Publicado: (2022)

Encoding Reversing Petri Nets in Answer Set Programming
por: Dimopoulos, Yannis, et al.
Publicado: (2020)

High-Throughput Network Communication with NetIO
por: Schumacher, J\"orn, et al.
Publicado: (2016)

Lessons Learned, Challenges Taken, and Actions Made for “Precision” Immunohistochemistry. Analysis and Perspectives From the NordiQC Proficiency Testing Program
por: Nielsen, Søren, et al.
Publicado: (2023)

Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age
por: Juul, Anders, et al.
Publicado: (2022)

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status
por: Jorge, Alexander A L, et al.
Publicado: (2022)

Call on me! Undergraduates’ perceptions of voluntarily asking and answering questions in front of large-enrollment science classes
por: Nadile, Erika M., et al.
Publicado: (2021)

Gender Differences in Student Comfort Voluntarily Asking and Answering Questions in Large-Enrollment College Science Courses
por: Nadile, Erika M., et al.
Publicado: (2021)

The impact of health insurance enrollment on health outcomes in Kenya
por: Mugo, Mercy G
Publicado: (2023)

A Synthetic dl-Nordihydroguaiaretic acid (Nordy), Inhibits Angiogenesis, Invasion and Proliferation of Glioma Stem Cells within a Zebrafish Xenotransplantation Model
por: Yang, Xiaojun, et al.
Publicado: (2014)

High-throughput and low-latency network communication with NetIO
por: Schumacher, Jorn, et al.
Publicado: (2017)

Determinants of facilitated health insurance enrollment for patients with HIV disease, and impact of insurance enrollment on targeted health outcomes
por: Furl, Renae, et al.
Publicado: (2018)

A NET Outcome
por: Lu, Thea, et al.
Publicado: (2012)

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Examining the Suitability of NetFlow Features in Detecting IoT Network Intrusions
por: Awad, Mohammed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r95jo6l2ccphsm1eq3v9vkqijq